Transkaryotic Therapies Replagal
Executive Summary
Company receives "complete review" letter for agalsidase alpha Jan. 1. FDA requests additional data and TKT "has initiated the collection of these data," the company says. Genzyme's Fabrazyme (agalsidase beta) is also receiving priority review at FDA for Fabry disease (1"The Pink Sheet" Dec. 18, 2000, p. 34)